115 completed, 17 terminated, 14 unknown, 5 withdrawn. 151 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 151 | Completed 115, Terminated 17, Unknown 14, Withdrawn 5 |
Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Bevacizumab, Atezolizumab, Sofosbuvir - Liver Cancer | Phase 4 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-03-17 | 2024-12-31 |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C | Phase 4 | Completed | Helwan University | 281 | 2020-11-21 | 2022-09-02 |
| Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] - Hepatitis C, Hemodialysis | Phase 4 | Completed | University of Pennsylvania | 6 | 2019-09-22 | 2021-12-15 |
| DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Sofosbuvir 400 mg and Daclatasvir 60 mg, Sofosbuvir 400 mg and Daclatasvir 90 mg, Ribavirin - Hepatitis C, Drug Use | Phase 4 | Completed | ANRS, Emerging Infectious Diseases | 979 | 2018-11-13 | 2023-10-26 |
| Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet - End-stage Renal Disease, HCV Coinfection | Phase 4 | Completed | Assiut University | 110 | 2018-05-01 | 2020-01-10 |
| Effect Of DAAs For Treatment Of HCV On Normal Kidney Sofosbuvir 400 MG Oral Tablet,, Ombitasvir/paritaprevir/ritonavir - Antiviral Drug Adverse Reaction | Phase 4 | Unknown | Assiut University | 100 | 2017-10-01 | 2017-09-29 |
| A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A elbasvir/grazoprevir, Sofosbuvir, Ribavirin - HCV | Phase 4 | Withdrawn | Fundacion SEIMC-GESIDA | 2017-07-01 | 2018-06-08 | |
| Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection. Ombitasvir-Paritaprevir-Ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis, C Virus | Phase 4 | Unknown | University of Modena and Reggio Emilia | 75 | 2016-12-01 | 2016-11-01 |
| DAA in the Risk of Recurrence After Curative Treatment of HCC Ledipasvir 90mg/Sofosbuvir 400 mg, Ribavirin - Hepatocellular Carcinoma | Phase 4 | Withdrawn | Taipei Veterans General Hospital, Taiwan | 2016-11-01 | 2017-08-07 | |
| Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients Sofosbuvir and Velpatasvir, Ribavirin - Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus | Phase 4 | Completed | National Taiwan University Hospital | 228 | 2016-08-01 | 2017-12-08 |
| A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection "3D" regimen, "3D" regimen with ribavirin - Hepatitis C, Chronic | Phase 4 | Completed | Kirby Institute | 87 | 2016-08-01 | 2019-06-13 |
| Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Zepatier, Ribavirin, Sofosbuvir - End-Stage Renal Disease, Hepatitis C | Phase 4 | Completed | Johns Hopkins University | 10 | 2016-07-20 | 2018-09-06 |
| Effect of Recombinant Human Interferon α-2b Spray on Herpangina Recombinant Human Interferon α-2b Spray, Ribavirin - Herpangina | Phase 4 | Completed | Children's Hospital of Fudan University | 668 | 2016-06-01 | 2019-03-07 |
| Study of Oral Treatments for Hepatitis C SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir) - Chronic Hepatitis C | Phase 4 | Completed | University of Florida | 1275 | 2016-06-01 | 2021-12-06 |
| Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study sofosbuvir/ledipasvir, sofosbuvir, Ribavirin - Liver Disease | Phase 4 | Terminated | University of Texas Southwestern Medical Center | 1 | 2016-02-25 | 2019-01-08 |
| Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection. Ribavirin - Hepatitis E | Phase 4 | Terminated | Hospital Universitari Vall d'Hebron Research Institute | 5 | 2015-12-01 | 2019-04-16 |
| Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment Paritaprevir, Ritonavir, Dasabuvir - Hepatitis C Virus | Phase 4 | Unknown | Nova Scotia Health Authority | 44 | 2015-07-10 | 2024-08-23 |
| Pilot HCV Direct Acting Antiviral Therapy and Metabolism ABT450r-ABT267-ABT333 +/- Ribavirin - Hepatitis C | Phase 4 | Completed | Ottawa Hospital Research Institute | 24 | 2015-07-01 | 2019-08-13 |
| Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO ombitasvir, paritaprevir/r, dasabuvir + ribavirin, ombitasvir, paritaprevir/r, dasabuvir - Hepatitis C, Chronic | Phase 4 | Completed | Kaiser Permanente | 200 | 2015-06-01 | 2021-01-22 |
Showing 20 of 151. Sign in to see all of them.
Hepatitis C, Chronic (85) · Hepatitis C (67) · HIV Infections (8) · Fibrosis (6) · Insulin Resistance (4) · Liver Diseases (4) · Acquired Immunodeficiency Syndrome (3) · Anemia, Hemolytic (3) · Carcinoma, Hepatocellular (3) · Coinfection (3) · Hemolysis (3) · Hepatitis (3) · Kidney Failure, Chronic (3) · Recurrence (3) · Fatty Liver (2)
Hoffmann-La Roche (27) · Merck Sharp & Dohme LLC (9) · National Taiwan University Hospital (7) · Kaohsiung Medical University Chung-Ho Memorial Hospital (5) · Kirby Institute (5) · Brooke Army Medical Center (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Ain Shams University (2) · Assiut University (2) · Baqiyatallah Medical Sciences University (2) · Beth Israel Medical Center (2) · Children's Hospital of Fudan University (2) · Germans Trias i Pujol Hospital (2) · Göteborg University (2) · Humanity and Health Research Centre (2)
United States (43) · Spain (14) · Taiwan (13) · Germany (9) · Australia (8) · Canada (8) · Italy (8) · Sweden (7) · Brazil (6) · Egypt (6) · France (6) · Puerto Rico (5) · United Kingdom (5) · Austria (4) · China (4)
Chen-Hua Liu, MD (6) · Ming-Lung Yu, MD, PhD (4) · Ding-Shinn Chen, MD (3) · Jia-Horng Kao, MD, PhD (3) · Shih-Jer Hsu, MD (3) · Bita Behnava, M.D. (2) · Bonaventura Clotet, MD, PhD (2) · Chang-Fu Chiu, MD (2) · Cheng-Chao Liang, MD (2) · Chia-Yen Dai, MD, Ms (2) · Chih-Lin Lin, MD (2) · Ching-Sheng Hsu, MD (2) · Chun-Jen Liu, MD, PhD (2) · Fariborz Mansour-Ghanaei, M.D. (2)
PMID 11984144, PMID 12375147, PMID 15191208, PMID 17302380, PMID 17484872, PMID 17625124, PMID 17875007, PMID 17943989, PMID 18081737, PMID 18508296, PMID 18684176, PMID 18834319, PMID 19144941, PMID 20163377, PMID 20377423, PMID 20816836, PMID 21064034, PMID 21145855, PMID 21205057, PMID 21281434, PMID 21282185, PMID 21439960, PMID 21506241, PMID 21714878, PMID 21784046, PMID 22235243, PMID 22592094, PMID 22927454, PMID 23428875, PMID 23442834, PMID 23593611, PMID 23795661, PMID 24297189, PMID 24360571, PMID 24747867, PMID 24997638, PMID 25105742, PMID 25557952, PMID 25645847, PMID 26057627, PMID 26094738, PMID 26115881, PMID 26130141, PMID 26327916, PMID 26867206, PMID 26890629, PMID 27228998, PMID 27246604, PMID 27355323, PMID 27782373
2004 (2), 2005 (2), K23DK082621 (1), R01DA016764 (1)